Jörgen Larsson1, Meidong Zhu, Florian Sutter, Mark C Gillies. 1. Department of Clinical Ophthalmology, Save Sight Institute, University of Sydney, GPO Box 4337, Sydney, NSW 2001, Australia. jorgen@eye.usyd.edu.au
Abstract
PURPOSE: To evaluate the correlation between improvement in visual acuity and the reduction of foveal thickness after a single intravitreal injection of 4 mg of triamcinolone in diabetic macular edema. DESIGN: Prospective, interventional, nonrandomized clinical trial. PATIENTS: In a prospective study 24 eyes with diabetic macular edema were treated with an intravitreal injection of 4 mg of triamcinolone acetonide. MAIN OUTCOME MEASURES: Best-corrected logMAR visual acuity and optical coherence tomography were performed at baseline and 3 months after the treatment. RESULTS: At baseline the average foveal thickness was 462 +/- 154 microm (95% confidence interval, 397-527 microm) and at 3 months 257 +/-114 microm (95% confidence interval, 209-305 microm) (P < .0001). The best-corrected logMAR average visual acuity was 60.5 +/- 10.5 (95% confidence interval, 56.0-65.0) ETDRS letters at baseline compared with 65.5 +/- 11.1 (95% confidence interval, 60.8-70.1) 3 months after the injection (P = .0001). There was no correlation between the improvement in visual acuity and the reduction of foveal thickness (r = 0.054, P = .8), but there was a correlation between reduction in foveal thickness and the age of the patients (r = 0.53, P = .008). CONCLUSION: A single injection of 4 mg of intravitreal triamcinolone acetonide effectively reduces the foveal thickness in diabetic macular edema and improves visual acuity, but there does not appear to be a strong correlation between the reduction of foveal thickness and the improvement in visual acuity.
PURPOSE: To evaluate the correlation between improvement in visual acuity and the reduction of foveal thickness after a single intravitreal injection of 4 mg of triamcinolone in diabetic macular edema. DESIGN: Prospective, interventional, nonrandomized clinical trial. PATIENTS: In a prospective study 24 eyes with diabetic macular edema were treated with an intravitreal injection of 4 mg of triamcinolone acetonide. MAIN OUTCOME MEASURES: Best-corrected logMAR visual acuity and optical coherence tomography were performed at baseline and 3 months after the treatment. RESULTS: At baseline the average foveal thickness was 462 +/- 154 microm (95% confidence interval, 397-527 microm) and at 3 months 257 +/-114 microm (95% confidence interval, 209-305 microm) (P < .0001). The best-corrected logMAR average visual acuity was 60.5 +/- 10.5 (95% confidence interval, 56.0-65.0) ETDRS letters at baseline compared with 65.5 +/- 11.1 (95% confidence interval, 60.8-70.1) 3 months after the injection (P = .0001). There was no correlation between the improvement in visual acuity and the reduction of foveal thickness (r = 0.054, P = .8), but there was a correlation between reduction in foveal thickness and the age of the patients (r = 0.53, P = .008). CONCLUSION: A single injection of 4 mg of intravitreal triamcinolone acetonide effectively reduces the foveal thickness in diabetic macular edema and improves visual acuity, but there does not appear to be a strong correlation between the reduction of foveal thickness and the improvement in visual acuity.
Authors: Dennis S C Lam; Carmen K M Chan; Shaheeda Mohamed; Timothy Y Y Lai; Kenneth K W Li; Patrick S H Li; Chi-Wai Tsang; Wai-Man Chan; Mahesh P Shanmugam Journal: Br J Ophthalmol Date: 2006-09-14 Impact factor: 4.638
Authors: E Hatef; M Hanout; A Moradi; E Colantuoni; M Bittencourt; H Liu; Y J Sepah; M Ibrahim; D V Do; D L Guyton; Q D Nguyen Journal: Eye (Lond) Date: 2014-08-08 Impact factor: 3.775
Authors: M Elizabeth Hartnett; Nicholas Tinkham; Lauren Paynter; Pete Geisen; Pinchas Rosenberg; Gary Koch; Kenneth L Cohen Journal: Am J Ophthalmol Date: 2009-10-17 Impact factor: 5.258